title: Experiences with semi-routine production of riboflavin and UV-B pathogen-inactivated platelet concentrates in three blood centres.
abstract: BACKGROUND
  For a clinical platelet (PLT) transfusion trial conducted in three countries, the production of PLT concentrates (PCs) that were pathogen inactivated with the Mirasol technology was set up and validated. While the Mirasol procedure is applied to an established PLT product, the PLT processing procedure still had to be modified to ensure a treated PC was of sufficient quality. Further, the effect of simulated transport conditions and the effect of ambient light on Mirasol-treated PCs was determined.
  
  
  METHODS
  Platelet concentrates in plasma were made from pooled buffy coats followed by Mirasol treatment. To mimic transport conditions, units were left unagitated for 6 h at room temperature. To mimic ambient light exposure, units were held unagitated for 4 h in direct fluorescent tube light.
  
  
  RESULTS
  Measures had to be taken to allow 7-day storage of treated concentrates. In one site, PCs made from five buffy coats with >450 × 109PLTs were removed from inventory. Another site went from five to four buffy coats per pool. Interruption of agitation for 6 h on day 3 did not induce meaningful changes in in vitro measures, even when stored up to 7 days. Exposure to ambient light for 4 h, either on day 3 or 6, had no effect on in vitro measures.
  
  
  CONCLUSIONS
  The Mirasol pathogen inactivation process can be implemented in routine, but changes to current PLT processing methods might be needed. Transport conditions and 4-h-long ambient light exposure have no negative effect on the in vitro quality of Mirasol-treated PCs.
authors.affiliation: Department of Product and Process Development, Sanquin Blood Bank, Amsterdam, The Netherlands.|Department of Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands.
authors.forename: P F
authors.initials: PF
authors.lastname: van der Meer
authors.affiliation: Canadian Blood Services, Ottawa, ON, Canada.
authors.forename: C
authors.initials: C
authors.lastname: Couture
authors.affiliation: Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway.
authors.forename: T
authors.initials: T
authors.lastname: Hervig
authors.affiliation: Department of Production, Sanquin Blood Bank, Amsterdam, The Netherlands.
authors.forename: G
authors.initials: G
authors.lastname: Kruit
authors.affiliation: Canadian Blood Services, Ottawa, ON, Canada.
authors.forename: D V
authors.initials: DV
authors.lastname: Devine
authors.affiliation: Department of Product and Process Development, Sanquin Blood Bank, Amsterdam, The Netherlands.
authors.forename: D
authors.initials: D
authors.lastname: de Korte
authors.affiliation: Department of Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands.|Department of Hematology, Haga Teaching Hospital, The Hague, The Netherlands.
authors.forename: J-L
authors.initials: JL
authors.lastname: Kerkhoffs
mesh_terms: D001792:Blood Platelets / Q000187:drug effects* / Q000528:radiation effects; D001793:Blood Preservation / Q000379:methods; D006801:Humans; D010976:Platelet Count; D012256:Riboflavin / Q000494:pharmacology*; D013696:Temperature; D014466:Ultraviolet Rays; D038301:Virus Inactivation / Q000187:drug effects / Q000528:radiation effects
chemical_list: D012256:Riboflavin
keywords: blood component production; blood components; blood processing; platelet components; platelet concentrates